Researchers at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) have developed a new approach using nanoparticles to fight medulloblastoma, the most prevalent malignant brain tumor in children.
This cutting-edge technology offers a more beneficial and, importantly, safe method of treating this complex illness, reassuring medical professionals and patients alike.
The Struggle and Battle Against Medulloblastoma
The development of medulloblastoma, a condition notoriously hard to treat due to the blood-brain barrier (BBB), may soon see a significant shift. A group led by doctors Ruirui Qiao and Helen Forgham has created an innovative iron oxide nanoparticle coated in fluoropolymer.
Dr. Qiao explained that their nanoparticles are not just any nanoparticles. They are uniquely designed to overcome the challenges posed by the blood-brain barrier (BBB). They are small enough to navigate through this barrier, durable sufficient to reach the tumor site, and made from materials easily detected by imaging technology.
This novel nanoparticle has two functions: it can be used for imaging and direct medication delivery to the brain tumor. Iron oxide makes up the nanoparticle's core, guaranteeing stability and endurance while allowing for accurate tumor imaging.
This dual functionality improves therapy accuracy and efficacy by enabling monitoring of the real-time treatment process. With these methods, the nanoparticle has the potential to revolutionize the treatment of this aggressive cancer, offering new hope to patients and their families.
What is Medulloblastoma?
Children between the ages of 3 and 8 are the most commonly affected by medulloblastoma, the most common malignant brain tumor in children. It starts in the base of the brain, the posterior fossa, also known as the cerebellum.
Balance, coordination, and motor control fall under this domain. Because the tumor can spread through cerebrospinal fluid to other areas of the brain and spinal cord, treatment can be complicated and risky.
Even with recent advancements in treatment, medulloblastoma continues to be a significant cause of cancer-related mortality in children. One major factor contributing to the difficulties of treating this cancer is the blood-brain barrier (BBB).
The blood-brain barrier (BBB) is a highly selective barrier that keeps many therapeutic medications from getting to brain tumors while shielding the brain from toxins and infections. As a result, conventional radiation and chemotherapy treatments frequently fall short, either failing to treat the cancer successfully or having severe adverse effects.
ALSO READ : New Anti-Cancer Drug Delivery Technology for Brain Tumors Is More Effective, Less Toxic [STUDY]
A Promising New Approach
The discovery of the new nanoparticles, published in the esteemed journal Advanced Science, demonstrates how these helpers may carry small interfering RNA (siRNA) straight to the tumor site. SiRNA slows tumor growth by silencing genes responsible for them without significantly harming healthy cells.
"This is a perfect demonstration of how chemistry and biology can work together to solve complex medical problems," stated Dr. Forgham. "Our nanoparticles can deliver targeted treatments that minimize damage to healthy cells, which is a significant advancement in pediatric cancer therapy."
Promising progress has been made towards clinical application with successful lab testing. The study team focuses on translating its discoveries into an effective patient treatment plan.
Dr. Forgham stated they aim to develop a product that provides a gentler yet highly effective approach to treating cancerous tumors. Although the primary focus is on medulloblastoma, he noted that this technology has the potential to be adapted for a broader range of cancers.
The creation of non-viral nanoparticles, such as those created by Drs. Forgham and Qiao are noteworthy advancements. These nanoparticles can pass through the blood-brain barrier and deliver cutting-edge gene-based medicines like siRNA and conventional chemotherapeutics.
This discovery may result in more potent therapies with fewer adverse effects, thereby enhancing the lives of young patients.
Check out more news and information on Cancer in Science Times.
